



## The 65th ASH Annual Meeting Abstracts

## ORAL ABSTRACTS

**617.ACUTE MYELOID LEUKEMIAS: BIOMARKERS, MOLECULAR MARKERS AND MINIMAL RESIDUAL DISEASE IN DIAGNOSIS AND PROGNOSIS****The Benefit of Allogeneic Transplant in 1<sup>st</sup> Complete Remission in *NPM1* Mutated AML with or without *FLT3* ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies**

Jad Othman, MBBS<sup>1,2,3</sup>, Nicola Potter, PhD<sup>1</sup>, Adam Ivey<sup>4</sup>, Jelena Jovanovic, PhD<sup>5</sup>, Sylvie D Freeman<sup>6</sup>, Amanda Gilkes<sup>7</sup>, Ian Thomas<sup>8</sup>, Sean Johnson<sup>8</sup>, Joanna Canham<sup>9</sup>, Jamie Cavenagh<sup>10</sup>, Panos Kottaridis<sup>11</sup>, Claire Arnold<sup>12</sup>, Ulrik Malthe Overgaard<sup>13</sup>, Mike Dennis, MDMRCP, FRCPath<sup>14</sup>, Charlotte Wilhelm-Benartzi<sup>7</sup>, Richard Dillon, PhD MRCP, FRCPath<sup>1,2</sup>, Nigel Russell<sup>15</sup>

<sup>1</sup> Department of Medical and Molecular Genetics, King's College London, London, United Kingdom

<sup>2</sup> Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

<sup>3</sup> Faculty of Medicine and Health, University of Sydney, Sydney, Australia

<sup>4</sup> Alfred Health, Melbourne, AUS

<sup>5</sup> King's College London, London, United Kingdom

<sup>6</sup> Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

<sup>7</sup> Cardiff University, Cardiff, GBR

<sup>8</sup> Cardiff University, Cardiff, United Kingdom

<sup>9</sup> Cardiff University, Cardiff, GBR

<sup>10</sup> Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, GBR

<sup>11</sup> University College London Hospital NHS Foundation Trust, London, GBR

<sup>12</sup> Belfast City Hospital, Belfast, GBR

<sup>13</sup> Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

<sup>14</sup> The Christie, Manchester, GBR

<sup>15</sup> Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom

**Background**

While there is accumulating evidence that measurable residual disease (MRD) negative patients with intermediate risk AML may not benefit from allogeneic transplantation in 1<sup>st</sup> complete remission (CR1-allo), many consider the presence of a *FLT3* Internal Tandem Duplication (ITD) an indication for this procedure. However, the studies supporting this practice were mainly performed before the development of sensitive molecular MRD techniques (Schlenk *NEJM* 2008). The UK NCRI AML17 and AML19 trials studied, then incorporated, MRD by RT-qPCR into the management of patients with *NPM1* mutated AML.

**Methods**

NCRI AML17 (April 2009 to December 2014) and AML19 (November 2015 to November 2020) were sequential prospective randomised trials for younger adults (18 - 60 years) with newly diagnosed AML. In AML17, decisions regarding CR1-allo were made using a validated risk score incorporating baseline factors and response to induction. In AML19, for patients with *NPM1* mutated AML (*NPM1*<sup>mut</sup>) the protocol recommended CR1-allo only in patients testing MRD positive in the peripheral blood (PB) post cycle 2 (PC2), regardless of other baseline risk factors such as *FLT3* ITD, based on findings from AML17 (Ivey *et al*, *NEJM* 2016). Both trials were performed prior to the availability of midostaurin and *FLT3* ITD MRD assays. Here we compare the outcomes of patients with *NPM1*<sup>mut</sup> in these trials and assess the benefit of CR1-allo according to *FLT3* ITD and molecular MRD status. Time-to-event variables are analysed using the Kaplan-Meier method, and the impact of alloSCT assessed using time-dependent Cox regression and visualised with Simon-Makuch plots. Molecular relapses were included as relapse events, and alloSCT performed after molecular relapse was not considered as CR1.

**Results**

737 patients with *NPM1*<sup>mut</sup> AML who achieved CR/CRi and had a valid PC2 PB MRD result were included in the analysis. 60/348 (17%) patients from AML17 and 83/389 (21%) from AML19 tested PB PC2 MRD positive. Overall, CR1-allo was performed in 20% of patients in AML17 and 25% in AML19. Of the MRD positive patients CR1-allo was performed in 16/60 (27%) in AML17

compared to 50/83 (60%) in AML19 where these patients were recommended for transplant. CR1-allo was performed in 18% and 16% of MRD negative patients in AML17 and AML19 respectively.

In AML17, as previously reported (Ivey *et al*, NEJM 2016), patients who were MRD+ had poor outcomes, with 3-year cumulative incidence of relapse (CIR) of 84% and overall survival (OS) of 25%. These outcomes were improved in AML19, with 3y CIR 50% and 3y OS 51%. Across both trials, CR1-allo was associated with a significant survival benefit in MRD+ patients (3y OS 61% vs 24%, HR 0.42, 95%CI 0.26-0.69,  $p < 0.001$ , Figure A). Patients who were MRD negative had excellent outcomes in both trials (3y CIR 33% and 24% and 3y OS 75% and 83% for AML17 and AML19 respectively). AlloSCT in CR1 provided no survival advantage for MRD- patients (HR 0.83, 95%CI 0.51-1.34,  $p = 0.4$ ).

There were a total of 286 patients with *NPM1*<sup>mut</sup> *FLT3* ITD<sup>mut</sup> AML with a PC2 PB MRD result across both trials. 81/286 (28%) were PB PC2 MRD+ of whom 32/81 (40%) received CR1-allo (28% in AML17 and 49% in AML19). Outcomes in these high-risk patients were improved in AML19, with 3y CIR 91% vs 68% and 3y OS 22% and 31% for AML17 and AML19 respectively. Those who received CR1-allo had improved outcomes (3y OS 45% vs 18%, HR 0.52, 95% CI 0.29-0.93,  $p = 0.03$ ) consistent with the overall MRD+ population.

In the 70% of *NPM1*<sup>mut</sup> *FLT3* ITD<sup>mut</sup> AML patients who achieved PB PC2 MRD-, outcomes were encouraging in both AML17 (3y CIR 37%, 3y OS 75%) and AML19 (3y CIR 27%, 3y OS 80%). CR1-allo was performed in 20% (19% in AML17, 21% in AML19), with no survival benefit for transplant (HR 0.80, 95% CI 0.37-1.72,  $p = 0.6$ , Figure B). There remained no benefit when restricted to those with high (>0.5) *FLT3* ITD allelic ratio (HR 0.63, 95% CI 0.2 - 2.23,  $p = 0.50$ ) and there was also no evidence of an interaction between allelic ratio and benefit from transplant for MRD negative patients ( $p = 0.86$ ).

### Conclusion

Molecular MRD can be used to stratify decision making concerning post remission therapy in patients with *NPM1*<sup>mut</sup> AML. Patients who achieve MRD negativity in the peripheral blood by the end of course 2 are at low risk of relapse and we found no evidence of benefit from allogeneic transplant in CR1, including in the subset with *FLT3* ITD. This finding contrasts with MRD+ patients where there was a significant survival benefit for CR1 transplant.

**Disclosures Freeman:** JAZZ: Research Funding, Speakers Bureau; BMS: Research Funding; MPAACT: Membership on an entity's Board of Directors or advisory committees; NOVARTIS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. **Dillon:** Astellas: Consultancy, Honoraria, Speakers Bureau; AvenCell: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Jazz: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Shattuck labs: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Research Funding; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. **Russell:** Astellas: Honoraria; Servier: Honoraria; Jazz Pharma: Research Funding; Pfizer: Honoraria, Research Funding, Speakers Bureau.




Figure 1

<https://doi.org/10.1182/blood-2023-179033>